NeoGenomics - NEO Stock Forecast, Price & News

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NEO. StockNews.com raised NeoGenomics to a "sell" rating in a research note on Saturday. The Goldman Sachs Group boosted their price objective on NeoGenomics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, August 10th. Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $16.00 and set a "buy" rating on the stock in a research report on Wednesday, August 10th. Piper Sandler started coverage on NeoGenomics in a research report on Thursday, June 2nd. They issued an "overweight" rating and a $13.00 target price on the stock. Finally, Morgan Stanley reduced their target price on NeoGenomics from $19.00 to $18.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.54.

NeoGenomics Trading Up 1.7 %

Shares of NEO Stock traded up $0.22 on Monday, hitting $12.84. The stock had a trading volume of 60,115 shares, compared to its average volume of 1,945,383. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.53 and a quick ratio of 7.26. The firm has a market capitalization of $1.62 billion, a P/E ratio of -10.64 and a beta of 0.94. NeoGenomics has a 1 year low of $6.85 and a 1 year high of $54.74. The company's 50 day moving average price is $9.00 and its 200-day moving average price is $12.66.

NeoGenomics (NASDAQ:NEO - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $125.00 million for the quarter, compared to the consensus estimate of $123.26 million. NeoGenomics had a negative return on equity of 8.53% and a negative net margin of 30.00%. The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) EPS. Analysts anticipate that NeoGenomics will post -1.04 earnings per share for the current year.